Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial

AIDS and Behavior

Volumn 18, Issue 5, 2014, Pages 841-848

  Mansoor, Leila Essop ^a   Karim, Quarraisha Abdool ^a   Werner, Lise ^a   Madlala, Bernadette ^a   Ngcobo, Nelisiwe ^a   Cornman, Deborah H ^a   Amico, K Rivet ^a   Fisher, Jeffrey ^a   Fisher, William A ^a   MacQueen, Kathleen M ^a   Karim, Salim S Abdool ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Adherence support; HIV prevention; Motivational interviewing; Tenofovir gel

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GEL; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; TOPICAL ANTIINFECTIVE AGENT;

ADULT; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGY; FEMALE; GEL; HEALTH BEHAVIOR; HIV INFECTIONS; HUMAN; INCIDENCE; INTERVENTION STUDY; MEDICATION COMPLIANCE; MOTIVATIONAL INTERVIEWING; PSYCHOLOGICAL MODEL; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; SOUTH AFRICA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DOUBLE-BLIND METHOD; FEMALE; GELS; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; INCIDENCE; INTERVENTION STUDIES; MEDICATION ADHERENCE; MODELS, PSYCHOLOGICAL; MOTIVATIONAL INTERVIEWING; ORGANOPHOSPHONATES; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84899643646     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-014-0752-9     Document Type: Article

References (25)

1. Lagakos S, Gable A, editors. Methodological challenges in biomedical HIV prevention trials. Washington, DC: National Academies Press; 2008. p 119-47.
2. Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
6. Anderson PL, Lama JR, Buchbinder S, et al., editors. Expanded case-control analysis of drug detection in the global iPrEx trial [abstract MOLBPE034]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011. Rome, Italy.
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.
8. MicrobicideTrialsNetwork. Press Release: Daily HIV prevention approaches didn't work for African women in VOICE study. http://www.mtnstopshiv.org/node/ 4877 (2013). Accessed 22 April 2013.
9. Marrazzo J, Ramjee G, Nair G, et al., editors. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Conference of Retroviral and Opportunistic Infections; 2013.Goergia World Congress Centre, Atlanta.
10. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep [Rev]. 2008;5(4):186-92.
11. Mauck CK, Straten A. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. J Acquir Immune Defic Syndr. 2008;49(1):64-9.
12. Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;23(17):2143-55.
13. Amico KR, McMahan V, Goicochea P, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16:1243-59.
14. Mansoor LE, Karim QA, Yende-Zuma N, et al. Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav. 2014. doi: 10.1007/s10461-014-0751- x.
15. Fisher JD, Fisher WA, Amico KR, et al. An information-motivation- behavioral skills model of adherence to antiretroviral therapy. Health Psychol [Rev]. 2006;25(4):462-73.
16. Ferrer RA, Morrow KM, Fisher WA, et al. Toward an information-motivation- behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997-1005.
17. Emmons KM, Rollnick S. Motivational interviewing in health care settings: opportunities and limitations. Am J Prev Med. 2001;20(1):68-74.
18. Rollnick S, Miller WR. What is motivational interviewing? Behav Cognit Psychother. 1995;23:325-34.
19. van der Straten A, Montgomery ET, Hartmann M, et al. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013;10(1):89-102.
20. Woodsong C, MacQueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013;16:18505.
21. Fisher JD, Cornman DH, Osborn CY, et al. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. J Acquir Immune Defic Syndr. 2004;37(Suppl 2):S78-87.
22. Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17(6):661-73.
23. Misovich S, Fisher J, Martinez T, et al. Predicting breast self-examination: a test of the information-motivation-behavioural skills model. J Appl Psychol. 2003;33:775.
24. Carey MP, Carey KB, Weinhardt LS, et al. Behavioral risk for HIV infection among adults with a severe and persistent mental illness: patterns and psychological antecedents. Community Ment Health J. 1997;33(2):133-42.
25. Mngadi KT, Maarschalk S, Grobler AC, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014. doi: 10.1007/s10461-014-0696-0.